We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Altria (MO) Q3 Earnings
Read MoreHide Full Article
The upcoming report from Altria (MO - Free Report) is expected to reveal quarterly earnings of $1.44 per share, indicating an increase of 4.4% compared to the year-ago period. Analysts forecast revenues of $5.32 billion, representing a decline of 0.4% year over year.
The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Altria metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenues net of excise taxes- Oral tobacco products' to come in at $713.65 million. The estimate indicates a year-over-year change of +2.7%.
The combined assessment of analysts suggests that 'Revenues net of excise taxes- Smokeable Products' will likely reach $4.64 billion. The estimate points to a change of -0.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Operating Income (Loss)/ Reported OCI- Oral tobacco products' should arrive at $486.18 million. The estimate compares to the year-ago value of $464.00 million.
According to the collective judgment of analysts, 'Adjusted OCI- Smokeable Products' should come in at $3.00 billion. Compared to the current estimate, the company reported $2.94 billion in the same quarter of the previous year.
Altria shares have witnessed a change of -1.6% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #2 (Buy), MO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Altria (MO) Q3 Earnings
The upcoming report from Altria (MO - Free Report) is expected to reveal quarterly earnings of $1.44 per share, indicating an increase of 4.4% compared to the year-ago period. Analysts forecast revenues of $5.32 billion, representing a decline of 0.4% year over year.
The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Altria metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenues net of excise taxes- Oral tobacco products' to come in at $713.65 million. The estimate indicates a year-over-year change of +2.7%.
The combined assessment of analysts suggests that 'Revenues net of excise taxes- Smokeable Products' will likely reach $4.64 billion. The estimate points to a change of -0.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Operating Income (Loss)/ Reported OCI- Oral tobacco products' should arrive at $486.18 million. The estimate compares to the year-ago value of $464.00 million.
According to the collective judgment of analysts, 'Adjusted OCI- Smokeable Products' should come in at $3.00 billion. Compared to the current estimate, the company reported $2.94 billion in the same quarter of the previous year.
View all Key Company Metrics for Altria here>>>Altria shares have witnessed a change of -1.6% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #2 (Buy), MO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .